Sucampo Pharmaceuticals Announces First Quarter 2013 Results and Operating Highlights Teleconference and Webcast
Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), a global pharmaceutical
company, today announced that it will host a webcast and teleconference
with senior management to discuss its financial results and operating
highlights for the first quarter ended March 31, 2013, on Tuesday, May
7, 2013, at 5:00 pm Eastern. The press release announcing the financial
results and operating highlights is expected to be released after the
close of the capital markets that day.
Investors interested in accessing the live audio webcast of the
teleconference may do so at http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-calendar
and should log on 10 to 15 minutes before the teleconference begins in
order to download any software required. Presentation slides will be
available via the webcast links. A replay of the webcast will also be
available on the Company’s website for several days after the live
event. Alternatively, investors may dial 877-703-6104 (domestic) or
857-244-7303 (international) and use passcode 54089443. A replay of the
teleconference will be available by dialing 888-286-8010 (domestic) or
617-801-6888, passcode 30982510, approximately two hours after the
teleconference concludes. The archive of the teleconference will remain
available for 30 days.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is a global pharmaceutical company focused
on innovative research, discovery, development and commercialization of
proprietary drugs based on prostones. The therapeutic potential of
prostones was first discovered by Ryuji Ueno, M.D., Ph.D., Ph.D.,
Sucampo’s Chairman, Chief Executive Officer, Chief Scientific Officer,
and co-founder. Prostones, naturally occurring fatty acid metabolites
that have emerged as promising compounds with unique physiological
activities, can be targeted for the treatment of unmet or underserved
medical needs. For more information, please visit www.sucampo.com.
Sucampo Forward-Looking Statement
This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve
risks and uncertainties, which may cause results to differ materially
from those set forth in the statements. The forward-looking statements
may include statements regarding product development, product potential,
future financial and operating results, and other statements that are
not historical facts. The following factors, among others, could cause
actual results to differ from those set forth in the forward-looking
statements: the impact of pharmaceutical industry regulation and health
care legislation; Sucampo's ability to accurately predict future market
conditions; dependence on the effectiveness of Sucampo's patents and
other protections for innovative products; the risk of new and changing
regulation and health policies in the U.S. and internationally and the
exposure to litigation and/or regulatory actions.
No forward-looking statement can be guaranteed and actual results may
differ materially from those projected. Sucampo undertakes no obligation
to publicly update any forward-looking statement, whether as a result of
new information, future events, or otherwise. Forward-looking statements
in this presentation should be evaluated together with the many
uncertainties that affect Sucampo's business, particularly those
mentioned in the risk factors and cautionary statements in Sucampo's
most recent Form 8-K and 10-K, which Sucampo incorporates by reference.
